UNLIMITED FREE ACCESS TO THE WORLD'S BEST IDEAS

close
Already an Engineering360 user? Log in.

This is embarrasing...

An error occurred while processing the form. Please try again in a few minutes.

Customize Your Engineering360 Experience

close
Privacy Policy

This is embarrasing...

An error occurred while processing the form. Please try again in a few minutes.

AAMI TIR105

Risk management guidance for combination products

active, Most Current
Buy Now
Organization: AAMI
Publication Date: 1 January 2020
Status: active
Page Count: 41
scope:

Inclusions

This TIR provides recommendations on the application of risk management principles and processes during development and marketing of combination products that include a device constituent part (drug−device, biological drug−device, or drug−device−biologic), in accordance with FDA's final rule (21 CFR Part 4) [11].4 These recommendations are intended to inform the adoption and application of established risk management processes during all phases of the lifecycle of combination products.

The recommendations and processes described in this TIR are intended to assist manufacturers of combination products in identifying hazards associated with the combination product, assessing associated risks, selecting options for controlling these risks, and monitoring the effectiveness of the implemented controls.

Exclusions

The TIR does not address drugs, biologics, or devices that are not part of a combination product, nor does it address drug−biologic combination products as risk management considerations for these are similar to those for drugs or biologics alone. Additionally, the TIR also does not address topics outside the realm of risk management for combination products. Finally, while the TIR might inform risk management practices for combination products marketed outside the United States, it is not intended, nor considered, to address non-U.S. practices or recommendations in all risk management considerations in a comprehensive fashion.

4 Among other things, Part 4 requires combination product manufacturers to comply with design control requirements, including requirements for risk management, consistent with 21 CFR 820.

Document History

AAMI TIR105
January 1, 2020
Risk management guidance for combination products
Inclusions This TIR provides recommendations on the application of risk management principles and processes during development and marketing of combination products that include a device constituent...

References

Advertisement